| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Cereblon (CRBN), a component of the E3 ubiquitin ligase complex, is the primary molecular target. This compound retains the thalidomide core that binds to CRBN, recruiting it to neo-substrates for ubiquitination and degradation.
|
|---|---|
| ln Vitro |
No specific in vitro activity data is available for this linker itself. As a building block, it is used to synthesize PROTACs which degrade target proteins in cell-free ubiquitination assays. The parent thalidomide shows IC50 of ~200 nM for CRBN binding.
|
| ln Vivo |
No specific in vivo activity data is available for this linker. The resulting PROTACs incorporating this linker have demonstrated in vivo efficacy in degrading targets in animal models of cancer, inflammation, and neurodegeneration, depending on the target protein ligand used.
|
| Enzyme Assay |
In a standard CRBN binding assay, the thalidomide derivative or its PROTAC conjugate is incubated with purified CRBN-DDB1 complex in buffer (50 mM Tris, pH 8.0, 100 mM NaCl, 1 mM DTT) for 1-2 hours at 4degC. Binding is detected by fluorescence polarization or surface plasmon resonance (SPR). No specific protocol for this linker alone is available.
|
| Cell Assay |
No specific cell-based protocol exists for this linker. However, for PROTACs synthesized from it, cells (e.g., HEK293T or cancer cell lines) are treated with the PROTAC (0.1 nM - 10 uM) for 4-48 hours. Target protein degradation is assessed by Western blot. The linker itself shows no cellular activity.
|
| Animal Protocol |
No standard in vivo protocol for this linker. For PROTACs containing it, typical protocols involve intravenous or intraperitoneal injection (e.g., 10-100 mg/kg) into tumor-bearing mice. Blood and tissues are collected at various time points to assess target degradation by Western blot or IHC.
|
| ADME/Pharmacokinetics |
PK properties are not applicable to the linker alone. For PROTACs containing this linker, they typically show moderate to high plasma protein binding, short to medium half-lives (1-6 hours in rodents), and are metabolized by CYP450 enzymes. Formulation often uses 10% DMSO, 40% PEG300, and 50% saline.
|
| Toxicity/Toxicokinetics |
General toxicity of the thalidomide core includes teratogenicity and potential for venous thromboembolism. However, the linker itself at low concentrations used in PROTAC synthesis is considered low risk. Standard lab safety precautions apply. This compound is not for human use.
|
| References |
[1]. Michael Bruno Plewe, et al. Compounds and methods of treating diseases. Patent WO2022068933A1.
|
| Additional Infomation |
Thalidomide-5-NH2-C8-NH2 TFA is a research-grade intermediate for PROTAC design. The C8 alkyl linker provides optimal spacing for ternary complex formation. The two NH2 groups allow for orthogonal protection and sequential conjugation. This product is for research use only, not for diagnostic or therapeutic applications.
|
| Molecular Formula |
C23H29F3N4O6
|
|---|---|
| Molecular Weight |
514.49477648735
|
| Exact Mass |
514.203
|
| CAS # |
2097509-49-2
|
| PubChem CID |
132260585
|
| Appearance |
Light yellow to green yellow solid powder
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
36
|
| Complexity |
722
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC(C(=O)O)(F)F.O=C1C2C=C(C=CC=2C(N1C1C(NC(CC1)=O)=O)=O)NCCCCCCCCN
|
| InChi Key |
NVUSVLWAQSTODF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H28N4O4.C2HF3O2/c22-11-5-3-1-2-4-6-12-23-14-7-8-15-16(13-14)21(29)25(20(15)28)17-9-10-18(26)24-19(17)27;3-2(4,5)1(6)7/h7-8,13,17,23H,1-6,9-12,22H2,(H,24,26,27);(H,6,7)
|
| Chemical Name |
5-(8-aminooctylamino)-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione;2,2,2-trifluoroacetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (194.37 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.86 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.86 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9437 mL | 9.7184 mL | 19.4367 mL | |
| 5 mM | 0.3887 mL | 1.9437 mL | 3.8873 mL | |
| 10 mM | 0.1944 mL | 0.9718 mL | 1.9437 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
